tbuckley/cabot-search huggingface dataset:
Abstract 9609: Impact of Mesenchymal Stem Cell Left Ventricular Implantation on Heart Rate Variability: Results From the POSEIDON Trial
Authors: Sachil Shah, Chad Brodt, Darcy L DiFede, Archana Ramireddy, James O Coffey, Juan F Viles Gonzalez, Suresh Atapattu, Alan W Heldman, Robert J Myerburg, Joshua M Hare, Raul D Mitrani
Journal: Circulation (2013)

Introduction: Patients (pts) with ischemic cardiomyopathy (ICM) may have impaired heart rate variability (HRV) which is associated with worse prognosis. We tested the hypothesis that cardiac mesenchymal stem cell (MSC) implantation is associated with improvement in HRV in patients with severe LV dysfunction and abnormal HRV at baseline Methods: The POSEIDON Trial evaluated transendocardial MSC implantation in pts with ICM. We examined 24-48 hour ambulatory monitoring data from 25 pts at baseline, immediately post MSC implant, and intermittently up to 13 months following implantation. HRV was assessed using 3 parameters: (1) standard deviation of NN intervals (SDNN), (2) the square root of the mean squared differences of successive NN intervals (RMSSD), and (3) standard deviation of the average normal NN intervals (SDANN). HRV indices were correlated to changes in ejection fraction (EF), end systolic volumes (ESV), end diastolic volumes (EDV), and sphericity index (SI) using t-test. Results: The cohort had a mean age of 62 ± 10 years, EF 26.5 ± 9.4%, ESV 204.2 ± 80.6 ml and EDV 271.5 ± 85.4 ml. Compared with pre-implantation values, RMSSD trended to improve in the cohort (30.2 ± 15 to 51.9 ± 39.3 msec, p=0.08), significantly improved in the group with EF improvement (24.6 ± 10 to 57.3 ± 43.5, p= 0.04) and tended to improve in the group with improved EDV, ESV, SI (Table). SDNN and SDANN also tended to improve in the cohort, but showed significant improvement in the group with less structural improvement noted by EDV or ESV decrease by &lt;5% (Table). Conclusions: There was a trend towards improvement in HRV after MSC implant. RMSSD, a variable more closely related with vagal tone, correlated better with greater improvements in EF, EDV, ESV and SI and may be a better marker of anatomical improvement. In contrast, SDNN and SDANN, which track not only vagal tone but diurnal variation, tended to improve in the overall cohort but showed improvement in the group with less structural improvement.
AB0008 Cross-talk between bone turnover and cardiovascular disease. association of micrornas expression, fracture and abdominal aortic calcifications
Authors: M.-E. Pickering, M. Croset, M. Millet, E. Sornay-Rendu, J.-C. Rousseau, O. Borel, P. Szulc, R. Chapurlat
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> MicroRNAs (miRs) have emerged as pivotal epigenetic key actors of gene regulation and several miRs have been shown to be at the crossroads of angiogenesis and of bone turnover, taking part in the calcification process by acting on osteoblasts and osteoclasts.<sup>1</sup> Calcification of the aortic media is highly regulated and involves numerous factors, including calcium deposal and other bone remodelling factors.<sup>2</sup> <h3>Objectives</h3> The objective of this study was to find a signature of miRs linked both to osteoporotic fracture risk and abdominal aortic calcification (AAC). The first outcome was the link between miRs levels at baseline and incident osteoporotic fractures (IOF) during 20 years; the second outcome was the link between miRs levels at baseline and the increase in AAC during 17 years. <h3>Methods</h3> Post-menopausal women older than 50 years from the OFELY cohort (Os des FEmmes de LYon) were selected if they had available serums at inclusion, and available data for each outcome. 3 miRs selected after literature review because of their impact on vascular calcification and bone turnover (miRs 26a-5p, 34a-5p, and 223–5 p) were measured at baseline. Bioassays of miRs was conducted with miRCURY Biofluids (Exiqon) extraction kit, TaqMan Life Technologies protocol, and QuantStudio 7 flex (Applied Biosystems) for RNA quantification. Results are expressed by relative quantification of Cycle threshold (Ct). <h3>Results</h3> A sample of 434 age-matched women (63 [57–72] years old), 50% with incident osteoporotic fracture during the 20 years of follow-up, was included. 183 women had available data to explore AAC; 93 had an increase in Kauppila score in 17 years (58 [55–61] years old), 90 did not (55 [53–58] years old). No significant link was underlined between miRs and IOF (miR-26: 1.06 [0.85–1.27] vs 0.99 [0.85–1.17], p=0.07; miR-34: 1.15 [0.53–1.87] vs 1.26 [0.60–2.07], p=0.35; miR-223: 1.01 [0.68–1.43] vs 1 0.05 [0.72–1.56], p=0.32). No miR was significantly linked to an increase in AAC (miR-26: 1.09 [0.94–1.28] vs 1.10 [0.89–1.30], p=0.95; miR-34: 0.78 [0.46–1.21] vs 0.73 [0.38–1.50], p=0.90; miR-223: 0.97 [0.69–1.22] vs 0.78 [0.56–1.22], p=0.11). <h3>Conclusions</h3> No association was observed between the 3 tested miRs and IOF or increase in AAC. Larger studies are necessary to select interesting epigenetic pathways reproductible on wider population. <h3>References</h3> [1] Krzeszinskia JY, Wei W, Huynh H, Jin Z, Wang X, Chang T-C, et al. miR-34a Blocks Osteoporosis and Bone Metastasis by Inhibiting Osteoclastogenesis and Tgif2. Nature2014Aug 28;512(7515):431. [2] Szulc P. Abdominal aortic calcification: A reappraisal of epidemiological and pathophysiological data. Bone2016Mar;84:25–37. <h3>Disclosure of Interest</h3> None declared
AB1402-HPR Validity of biodex balance system in fibromyalgia patients
Authors: F Söke, A. Güclü Gündüz, C. Gülsen, Y. Aydın, K. Cekim, D. Akcalı
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Fibromiyalgia (FM) patients are commonly suffer from balance problems and increased fall frequency. However, validity of any measurement tool has not been determined in clinical trials. Modified Clinical Test of Sensory Interaction and Balance Test (M-CTSIB) is a simple and easily administered test. <h3>Objectives</h3> The aim of the study was to investigate the validity and reliability of the M-CTSIB in FM patients. <h3>Methods</h3> Twenty-one FM patients and 15 age matched controls were evaluated M-CTSIB. M-CTSIB was evalueted by Biodex-BioSway<sup>TM</sup> (Biodex Inc., Shirley, New York)]. M-CTSIB evaluates the relationship between balance and visual, somatosensory and vestibular system. Tests carried out were 4 conditions, condition-1: eyes open-firm surface, condition-2: eyes closed-firm surface, condition 3: eyes open-foam surface, and condition 4: eyes closed-foam surface, for 30 s intervals with two repetitions. Body oscillations of the participants were calculated by the system and Sway Index scores obtained. High scores indicate high postural sway of the test subject. <h3>Results</h3> The results of this study, FM patients had significantly impaired balance in all conditions of M-CTSIB compared to controls (p&lt;0.05). Discriminatory power of all subcomponents of M-CTSIB between groups was excellent. The ROC areas under the curves were 0.803 for condition-1, 0.757 for condition-2, 0.833 for condition-3, 0.776 for condition-4 (AUC=0.803, AUC=0.757, AUC=0.833, AUC=0.776, respectively). <h3>Conclusions</h3> These results suggest that FM may lead to increase balance problems. M-CTSIB has been proved to be valid, objective and clinically useful method to detect balance impairments in FM patients. <h3>Disclosure of Interest</h3> None declared
SP0103 Indications and clinical implications of mr imaging in ra
Authors: B. Ostendorf
Journal: Annals of the Rheumatic Diseases (2018)

<h3></h3> In clinical practice, rheumatologists most frequently use imaging techniques to explore bone and soft-tissue involvement in RA. MRI is the best noninvasive, observer-independent imaging modality technique that has advantages over clinical examination and conventional radiographs for assessing joint damage and soft tissue inflammation, which are common features even in the earliest stages of RA. MRI provides multiplanar images with a high degree of resolution without ionising radiation. Based on these characteristics, MRI identifies early signs of arthritis where other imaging modalities failed. Main indications for MRI in RA consequently are to determine joint involvement, differential diagnosis and early diagnosis of inflammation, such as synovial changes, changes in tendon sheaths and bursae, as well as bone marrow oedema (BME), not detected by clinical examination, BME even also not by ultrasound. The presence of BME has added benefits to modern diagnostic criteria, and anti-citrullinated peptide antibody positive patients have demonstrated higher osteitis scores. Additionally, MRI helps to assess and define prognosis and outcome, because synovitis and BME are risk factors for the progression of structural changes. Growing data on the validity of MRI in predicting and assessment of treatment response are available as well. Recent evidence has demonstrated that MRI inflammatory parameters are frequent findings in RA with clinical remission and low disease activity states, which has impact on treatment changes. MRI helps to identify at-risk individuals with arthralgia without clinical arthritis, furthermore these patients with defined RA and high risk for disease progression leading to therapy escalation and also may limit unnecessary treatment with potentially expensive biologic drugs. Studies that directly assess how MRI use in clinical care might even influence decision making, quality of care and cost effective delivery of that care. Clinical studies answering these questions of regular use of MRI are warranted. <h3>Disclosure of Interest</h3> None declared
AB1280 Predicting work disability, pension claim, absenteeism and presenteeism in ra patients
Authors: A.D. Houssien, M. Yates, S. Norton, J. Galloway
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Despite advances in treatments for Rheumatoid Arthritis (RA) a high prevalence of unemployment and work disability (WD) is reported; almost one third of affected patients leave the work force within two years of diagnosis. However, historic studies focused upon work disability as a dichotomous outcome, whereas more recent research has shifted the focus to work productivity, absenteeism and presenteeism. <h3>Objectives</h3> We undertook a systematic review of observational studies to identify the known predictors of work productivity from work disability and identify the gap in between. <h3>Methods</h3> A systematic search of Medline and Embase and PsychINFO since 2000 was undertaken using search terms: "Rheumatoid arthritis", "Disability", "Employment", "Work", "Occupation", "presenteeism", "absenteeism", "productivity" and "indirect cost". Original publications, all observational studies, reporting on predictors of work outcomes in RA were eligible. Clinical trials of drug therapies were excluded. All article titles were manually reviewed by 2 reviewers (AH and MY) and relevant abstracts was discussed and agreed, for which full text articles were sourced. Selected articles were assessed for quality using: QUality In Prognosis Studies (QUIPS) for observational studies. The heterogeneity in study designs meant meta-analysis was not appropriate. Therefore, To account for variation across studies in outcome measures used, an albatross plot was used to confirm predictors that were significantly associated with adverse work outcome. <h3>Results</h3> In total 57 observational studies were included in the review, with data collectively on 83 686 patients. The studies were from 19 different countries, predominantly including developed countries. There was substantial heterogeneity across studies in terms of predictors evaluated as well as how work productivity was estimated. More contemporary studies were more likely to capture information on mental health as a predictor. Consistent significant predictors of work outcome could be divided into<sup>1</sup> demographic factors: older age, obesity, lower educational level, job type, commuting difficulty;<sup>2</sup> disease factors: higher disease activity, longer disease duration, joint erosions, longer morning stiffness, higher disability;<sup>3</sup> comorbidity: concomitant mental health disorder, fibromyalgia or cardiovascular disease. <h3>Conclusions</h3> The review highlights the lack of consistency in the use of validated work outcome measures in research. The key determinant of work disability extends beyond disease severity measures, and in particular mental health is emerging as a pivotal component of health that predicts ability to remain within the work force. <h3>Disclosure of Interest</h3> None declared
Genetic diagnosis of primary immunodeficiencies: A survey of the French national registry
Authors: Nizar Mahlaoui, Capucine Picard, Perrine Bach, Laurence Costes, Virginie Courteille, Anja Ranohavimparany, Alexandre Alcaïs, Jean-Philippe Jais, Alain Fischer, Christine Bellanné-Chantelot, Jacinta Bustamante, Sylvie Chollet-Martin, Christian Drouet, Véronique Fremeaux-Bacchi, Caroline Kannengiesser, Virginie Girardin, Nathalie Lambert, Valérie Proulle, Jérémie Rosain, Marie José Stasia, Dominique Stoppa Lyonnet, Ioannis Theodorou, Wadih Abou-Chahla, Daniel Adoue, Nathalie Aladjidi, Zahir Amoura, Corinne Armari-Alla, Brigitte Bader-Meunier, Vincent Barlogis, Sophie Bayart, Yves Bertrand, Stéphane Blanche, Damien Bodet, Bernard Bonnotte, Raphaël Borie, Patrick Boutard, Claire Briandet, Jean-Paul Brion, Jacques Brouard, Liana Carausu, Emilie Catherinot, Nathalie Cheikh, Sarah Cohen-Beaussant, Louis-Jean Couderc, Pierre Cougoul, Gérard Couillault, Geneviève de Saint Basile, Catherine Devoldere, Anne Deville, Eric Dore, Fabienne Dulieu, Isabelle Durieu, Natacha Entz Werle, Claire Fieschi, Fanny Fouyssac, Pierre Frange, Vincent Gajdos, Lionel Galicier, Virginie Gandemer, Martine Gardembas, Catherine Gaud, Bernard Grosbois, Aurélien Guffroy, Corinne Guitton, Gaelle Guillerm, Eric Hachulla, Mohamed Hamidou, Sophie Haro, Yves Hatchuel, Olivier Hermine, Cyrille Hoarau, Bruno Hoen, Arnaud Hot, Sébastien Humbert, Arnaud Jaccard, Serge Jacquot, Rolland Jaussaud, Pierre-Yves Jeandel, Eric Jeziorski, Kamila Kebaili, Anne-Sophie Korganow, Olivier Lambotte, Fanny Lanternier, Claire Larroche, Alain Le Quellec, Emmanuelle Le Moigne, Vincent Le Moing, David Launay, Yvon Lebranchu, Marc Lecuit, Guillaume Lefevre, Richard Lemal, Valérie Li-Thiao-Te, Olivier Lortholary, Marion Malphettes, Aude Marie-Cardine, Nicolas Martin Silva, Agathe Masseau, Christian Massot, Françoise Mazingue, Etienne Merlin, Gérard Michel, Frédéric Millot, Béatrice Monlibert, Fabrice Monpoux, Despina Moshous, Luc Mouthon, Martine Munzer, Bénédicte Neven, Raphaëlle Nove-Josserand, Dalila Nouar, Eric Oksenhendler, Marie Ouachée-Chardin, Anne Pagnier, Marlène Pasquet, Isabelle Pellier, Yves Perel, Antoinette Perlat, Christophe Piguet, Dominique Plantaz, Pierre Quartier, Frédéric Rieux-Laucat, Pascal Roblot, Pierre-Simon Rohrlich, Bruno Royer, Valéry Salle, Françoise Sarrot-Reynauld, Amélie Servettaz, Jean-Louis Stephan, Nicolas Schleinitz, Felipe Suarez, Laure Swiader, Sophie Taque, Caroline Thomas, Olivier Tournilhac, Caroline Thumerelle, Jean-Pierre Vannier, Jean-François Viallard
Journal: Journal of Allergy and Clinical Immunology (2019)
Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation
Authors: Anthony R. Mato, Jakub Svoboda, Eline T. Luning Prak, Stephen J. Schuster, Patricia Tsao, Colleen Dorsey, Pamela S. Becker, Danielle M. Brander, Sunita Dwivedy Nasta, Daniel J. Landsburg, Cara M King, Beth Morrigan, Kaitlin Kennard, Lindsey E. Roeker, Andrew D. Zelenetz, Michelle Purdom, Dana Paskalis, Peter Sportelli, Hari P Miskin, Michael S. Weiss, Mazyar Shadman
Journal: Blood (2018)
SP0130 Towards t cell tolerance in rheumatoid arthritis
Authors: R. Thomas
Journal: Annals of the Rheumatic Diseases (2018)

<h3></h3> Disease modifying strategies are available for treatment of rheumatoid arthritis (RA), and good response rates are achieved. However, limitations include toxicity, a response rate ceiling, cost and rationing of biologic therapies, inability to cure or permanently reverse RA pathology, and inability to prevent disease. Immunotherapies targeting checkpoint molecules are markedly changing the landscape of clinical oncology. In autoimmune diseases such as RA, dendritic cells represent an important target for antigen-specific immunotherapy for T cell tolerance. Antigen-specific strategies promise greater specificity and safety, without general immune suppression, and thus the potential for intervention in at-risk subjects before disease onset. In a proof-of-concept trial, delivery of autoantigenic peptides and autologous tolerogenic dendritic cells was safe and had immunomodulatory effects on T cells including reduction of effector T cells and a relative increase in regulatory T cells. We have developed and are trialling in RA patients, antigen-specific immunotherapy targeting dendritic cells <i>in situ</i> with liposomes encapsulating autoantigenic peptide and calcitriol with the aim of antigen-specific T cell tolerance. I will discuss the development of antigen-specific tolerance strategies and the parallel development of immune monitoring assays to determine T cell outcomes in clinical trials in RA. <h3>Disclosure of Interest</h3> R. Thomas Grant/research support from: Janssen Biotech Inc, Consultant for: Janssen Biotech Inc
Long-Term Implications of Atrial Fibrillation in Patients With Degenerative Mitral Regurgitation
Authors: Francesco Grigioni, Giovanni Benfari, Jean-Louis Vanoverschelde, Christophe Tribouilloy, Jean-Francois Avierinos, Francesca Bursi, Rakesh M. Suri, Federico Guerra, Agnés Pasquet, Dan Rusinaru, Emanuela Marcelli, Alexis Théron, Andrea Barbieri, Hector Michelena, Siham Lazam, Catherine Szymanski, Vuyisile T. Nkomo, Alessandro Capucci, Prabin Thapa, Maurice Enriquez-Sarano, R. Suri, M.A Clavel, J. Maalouf, H. Michelena, Vuyisile T. Nkomo, M. Enriquez-Sarano, C. Tribouilloy, F. Trojette, C. Szymanski, D. Rusinaru, G. Touati, J.P. Remadi, F. Guerra, A. Capucci, F. Grigioni, A. Russo, E. Biagini, F. Pasquale, M. Ferlito, C. Rapezzi, C. Savini, G. Marinelli, D. Pacini, G.D. Gargiulo, R. Di Bartolomeo, J. Boulif, C. de Meester, G. El Khoury, B. Gerber, S. Lazam, A. Pasquet, P. Noirhomme, D. Vancraeynest, J-L. Vanoverschelde, J.F. Avierinos, F. Collard, A. Théron, G. Habib, A. Barbieri, F. Bursi, F. Mantovani, R. Lugli, M.G. Modena, G. Boriani, L. Bacchi-Reggiani
Journal: Journal of the American College of Cardiology (2019)
FRI0212 The relationship between anti-tnf therapy use and metabolic syndrome in patients with ankylosing spondylitis
Authors: A. Ferhatosmanoğlu, S. Çelik, N. Alpay Kanıtez, N. Caf, S. Yilmaz-Oner, C. Bes
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Ankylosing spondylitis (AS) is an inflammatory disease associated with accelerated atherosclerosis and the presence of metabolic syndrome (MetS) features. TNF-α is considered as one of the factors responsible for favouring insulin resistance and dyslipidemia, which are important features of the metabolic syndrome. <h3>Objectives</h3> In this study, we aimed to investigate the relationship between anti-TNF therapy and metabolic syndrome rate in patients with ankylosing spondilitis (AS). <h3>Methods</h3> AS patients who visited the outpatient rheumotology clinic between 2016 February and May were included in to the study. Systolic and diastolic blood pressures, body mass index (BMI), waist-hip circumference were measured. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), fasting blood sugar, cholesterol panel were evaluated. MetS was defined by abdominal obesity, elevated blood pressure, elevated glucose, high triglycerides and reduced high-density lipoprotein cholesterol according to National Cholesterol Education Program's Adult Treatment Panel III report (NCEP ATP III) criteria. Duration of disease and use of anti-TNF was recorded. Bath Ankylosing Spondylitis Functional Index (BASFI) – Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) measurements were performed to assess the disease activity and functional capacities. Patients were divided into two groups as anti-TNF treated and anti-TNF naive. For comparisons between groups statistical analyses included descriptive statistics, <i>t</i>- tests and one-way ANOVA. <h3>Results</h3> A total of 223 patients were analysed. Of the total 223 patients, 78 (35%) were receiving anti-TNF therapy. Age distribution was similar in between groups. In the group receiving anti-TNF therapy, the number of male patients was higher (75.6% vs. 58.6%) and the duration of disease was longer (145.2±90.8 vs 103.3±97.1). Serum lipid levels, glucose, ESR, CRP, BASFI, BASDAI measurements, BMI and blood pressures were not significantly different in between the groups. MetS was present in 26 (33.3%) of 78 patients receiving anti-TNF and 29 (20%) of 145 patients in anti-TNF naive group. The effect of TNF-α inhibitor use on MetS was independent from the gender. <h3>Conclusions</h3> Patients with AS who received anti-TNF therapy were found to have a higher incidence of MetS than those who did not. Suppression of the catabolic effect of inflammation with treatment may have been effective in this result. <h3>Disclosure of Interest</h3> None declared
A monoallelic activating mutation in RAC2 resulting in a combined immunodeficiency
Authors: Vassilios Lougaris, Janet Chou, Abdallah Beano, Jacqueline G. Wallace, Manuela Baronio, Luisa Gazzurelli, Tiziana Lorenzini, Daniele Moratto, Giovanna Tabellini, Silvia Parolini, Michael Seleman, Kelsey Stafstrom, Haiming Xu, Chad Harris, Raif S. Geha, Alessandro Plebani
Journal: Journal of Allergy and Clinical Immunology (2019)
FRI0457 Relationship between digital ulcers and severity of lung function test in systemic sclerosis over a five-year period
Authors: O.B. Ovsyannikova, O. Koneva, L. Ananieva
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Systemic sclerosis-related interstitial lung disease (SSc-ILD) is the leading cause of death in SSc. Predictors of the outcomes of ILD in SSc are under investigation. <h3>Objectives</h3> to assess association of the digital ulcers with dynamics of forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLco) in patients with SSc-ILD. <h3>Methods</h3> It was a longitudinal study involving 83 pts with SSc-ILD (mean age was 46,2±13,4; 69% have limited subset of the disease; 95% were female). The mean duration of follow up was 58,9±12,0 months. At the end of the study a number of pts with digital ulcers (DUs) was 29 (35%). Additionally 77 pts. with SSc-ILD were investigated with HRCT and were divided into 3 groups; The 1 st group (16 pts) with improvement; 2nd group (39 pts) without any changes and 3rd group (22 pts) with worsening of fibrosis. <h3>Results</h3> After 5 years of follow up FVC increased significantly in all pts without DUs (n=54) from 88,5%±19 to 96%±23 (p&lt;0,05); in group 1 – from 92%±20.5 to 106%±19 (p&lt;0,05); in group 2 from 87%±18 to 94%±23.5 (p&lt;0,05) and only in group 3 FVC was stable (88±22 and 87±24.5) (p&gt;0,05). The mean value of FVC in all pts with DUs didn't change (88%±14 and 86%±16, p&gt;0,05) with tendency to decreasing in group 3 (from 83%±12,5 to 74%±13 (p&gt;0,05). After 5 years of follow up DLco declined significantly in all pts with or without DUs, however in the 1 st group decline of DLco wasn't significant. The decreasing of DLCO was more prominent in group 3 than in group 2. Therefore, in group 2 in patient without DU (n=24) – from 65%±16 to 60%±11 (p&lt;0,05) and in patients with DU (n=14) DLCO changed from 61%±15 to 57%±14 (p&lt;0,05). In 3rd group in patients without DU (n=13) DLCO decreased from 55%±15 to 48%±15 (p&lt;0,05) and in patients with DU (n=9)- from 50%±20 to 44,5%±15 (p&lt;0,05). <h3>Conclusions</h3> In patients without DUs significant increasing of FVC during 5 years long follow up was observed. The worsening of fibrosis on HRCT in pts with DUs was associated with the lowest value of FVC and DLco at the entry and at the end of the study. <h3>Disclosure of Interest</h3> None declared